766519-89-5

Usage

Uses

Used in Pharmaceutical Development:
5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs with diverse therapeutic profiles. Its unique structure allows for the creation of molecules that can interact with specific biological targets, potentially leading to treatments for various diseases and conditions.
Used in Agrochemical Research:
In the agrochemical industry, 5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine is utilized as a starting material for the design and synthesis of novel agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control, crop protection, and other agricultural applications, contributing to increased crop yields and reduced chemical dependence.
Used in Materials Science:
5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine is employed as a component in the development of advanced materials with specific properties. Its unique chemical structure can be leveraged to create materials with tailored characteristics for use in various industries, such as electronics, coatings, and adhesives.
Used in Medicinal Chemistry Research:
As a valuable tool in medicinal chemistry, 5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine is used in the exploration of new chemical entities and the optimization of lead compounds. Its reactivity and structural features facilitate the discovery of bioactive molecules with potential therapeutic applications.
Used in Chemical Biology Studies:
5-(3-fluoro-phenyl)-2H-pyrazol-3-ylamine is utilized in chemical biology to investigate the interactions between small molecules and biological systems. Its unique structure allows for the probing of molecular mechanisms and the development of compounds that can modulate biological processes for research purposes.

InChI:InChI=1/C9H8FN3/c10-7-3-1-2-6(4-7)8-5-9(11)13-12-8/h1-5H,(H3,11,12,13)

Upstream product

• 21667-61-8 3-fluorobenzoylacetonitrile 
• 455-68-5 methyl 3-fluorobenzoate 
• 456-48-4 3-Fluorobenzaldehyde 
• 455-38-9 3-fluorobenzoic acid 

Downstream Products

• 948881-91-2 C₁₈H₂₃FN₄O 
• 1606126-30-0 4-chloro-3-(3-fluorophenyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]-5-phenyl-pyrazolo[3,4-c]pyridazine 
• 1606126-31-1 4-[2-[4-chloro-3-(3-fluorophenyl)-5-phenyl-pyrazolo[3,4-c]pyridazin-1-yl]ethyl]morpholine 
• 1606126-53-7 4-chloro-3-(3-fluorophenyl)-5-phenyl-1H-pyrazolo[3,4-c]pyridazine 
• 1606126-52-6 3-(3-fluorophenyl)-4-(2-phenylethynyl)-1H-pyrazol-5-amine 
• 1606126-51-5 N-[3-(3-fluorophenyl)-4-(2-phenylethynyl)-1H-pyrazol-5-yl]acetamide 
• 1606126-50-4 N-[3-(3-fluorophenyl)-4-iodo-1H-pyrazol-5-yl]acetamide 
• 1606126-49-1 N-[3-(3-fluorophenyl)-1H-pyrazol-5-yl]acetamide 
• 1363184-52-4 3-(3-fluoro-phenyl)-4-hydroxy-4-trifluoromethyl-1,4,5,7-tetrahydro-pyrazolo[3,4-b]pyridin-6-one 
• 1269515-38-9 2-(3-fluorophenyl)-6-nitropyrazolo[1,5-a]pyrimidine 
• 1269515-39-0 2-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-6-amine 
• 1269515-37-8 2,6-difluoro-N-(2-(3-fluorophenyl)pyrazolo[1,5-a]pyrimidin-6-yl)-3-(propylsulfonamido)benzamide 

Relevant academic research and scientific papers

Synthesis of Pyrazole Compounds by Using Sonication Method

A simple method for the synthesis of pyrazoles derivatives carried out by cyclization of cyanide with hydrazine hydrate by using sonication method. All the prepared compounds were characterized by 1H, 13C NMR and IR Spectroscopy.

ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

Modular synthesis and antiproliferative activity of new dihydro-1H-pyrazolo[1,3-b]pyridine embelin derivatives

A set of new dihydro-1H-pyrazolo[1,3-b]pyridine and pyrazolo[1,3-b]pyridine embelin derivatives was synthesized through a multicomponent reaction from natural embelin, 3-substituted-5-aminopyrazoles and aldehydes. The synthesized compounds were evaluated against three hematologic tumor cell lines, HEL (acute erythroid leukemia), K-562 (chronic myeloid leukemia) and HL-60 (acute myeloid leukemia), and five breast cancer cell lines (SKBR3, MCF-7, MDA-MB-231, BT-549, HS-578T). The primate non-malignant kidney Vero cell line was used as the control of cytotoxicity. From the obtained results, some structure–activity relationships were out-lined. Furthermore, in silico prediction of physicochemical properties and ADME parameters were determined for the derivatives with the best antiproliferative values.

N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate

α7 nicotinic acetylcholine receptors (α7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the α7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can a

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.